List of Excipients in Branded Drug PHENTERMINE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing PHENTERMINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Eon Labs Inc	phentermine hydrochloride	0185-0644	D&C YELLOW NO. 10
Eon Labs Inc	phentermine hydrochloride	0185-0644	FD&C BLUE NO. 1
Eon Labs Inc	phentermine hydrochloride	0185-0644	FD&C RED NO. 3
Eon Labs Inc	phentermine hydrochloride	0185-0644	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in PHENTERMINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	ACID RED 51
1	ACID RED 92
1	ACID YELLOW 3
57	ALCOHOL

Phentermine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Phentermine hydrochloride is an established, low-cost sympathomimetic anorectic with limited compound-patent protection and a largely generic market. Commercial opportunity is concentrated in differentiated dosage forms, dose flexibility, adherence, supply reliability, and lifecycle positioning rather than in basic 37.5 mg immediate-release tablets.

The strongest excipient strategies are low-cost, robust immediate-release products; orally disintegrating or rapidly dispersible tablets; low-dose products that support titration; and formulations designed to improve manufacturability, stability, or patient acceptability without implying extended treatment or abuse-deterrent performance.

What is the FDA regulatory status of phentermine hydrochloride?

Phentermine hydrochloride is an FDA-approved prescription drug for short-term use as an adjunct to caloric restriction and exercise in the management of exogenous obesity. FDA labeling states that treatment is generally intended for a few weeks and that phentermine is indicated as monotherapy rather than in combination with other weight-loss drugs, including serotonergic agents such as selective serotonin reuptake inhibitors, unless specifically directed by a physician. [1][2]

Regulatory attribute	Phentermine hydrochloride
Therapeutic class	Sympathomimetic amine anorectic
Common dosage forms	Immediate-release tablets and capsules
Typical strengths	8 mg, 15 mg, 30 mg, 37.5 mg
FDA pathway	NDA and abbreviated new drug application pathways
Controlled-substance status	Schedule IV under the federal Controlled Substances Act
Primary indication	Short-term adjunct in obesity management
Common reference products	Adipex-P, Lomaira
Biosimilar exposure	None
Primary generic route	ANDA, subject to reference-product and labeling requirements

Phentermine is marketed as the hydrochloride salt. The active pharmaceutical ingredient is a basic amine, so formulation development must control salt form, moisture exposure, blend uniformity, content uniformity, and dissolution performance.

What formulations are protected by phentermine hydrochloride patents?

No major active-molecule patent barrier is generally associated with conventional phentermine hydrochloride immediate-release tablets or capsules. The principal commercial products have been on the market for decades, and generic competition is established.

The relevant intellectual-property analysis is therefore formulation-specific:

• Immediate-release tablet composition patents, if any, are unlikely to block standard generic entry where the formulation is materially different or the claims have expired.
• Drug-delivery patents could become relevant for orally disintegrating, chewable, multiparticulate, modified-release, or abuse-deterrent products.
• Method-of-use claims could affect a new indication or dosing regimen, but conventional short-term obesity treatment has limited room for broad exclusivity.
• Manufacturing-process patents may protect granulation, coating, particle engineering, or controlled-release processes without preventing all generic products.
• Trademark and trade-dress rights remain commercially relevant for branded packaging, but they do not block ANDA approval if the generic avoids protected branding.

Applicants should verify live claims in the USPTO Patent Center, FDA Orange Book, and relevant state litigation records before relying on any formulation-based exclusivity position. The Orange Book is the controlling FDA source for listed patents and regulatory exclusivity tied to approved drug products. [3]

When does phentermine hydrochloride lose exclusivity?

Phentermine hydrochloride has already lost the exclusivity associated with a new chemical entity. Conventional generic entry is therefore the baseline commercial condition.

The practical exclusivity profile is:

Exclusivity category	Current commercial significance
New chemical entity exclusivity	Expired
Original composition-of-matter patent	Expired or no longer commercially controlling
Pediatric exclusivity	No known broad market barrier for standard products
Orphan-drug exclusivity	Not applicable to conventional obesity treatment
Biologic exclusivity	Not applicable
Formulation exclusivity	Product-specific and requires live claims
Method-of-use exclusivity	Potentially available only for a new, FDA-recognized use
180-day generic exclusivity	Possible for a first Paragraph IV filer, depending on the product and litigation outcome

For a new conventional ANDA, the commercial issue is not whether phentermine can be copied, but whether the applicant can obtain approval with competitive cost, reliable supply, and a product that is meaningfully differentiated from existing tablets and capsules.

What is the Orange Book status of phentermine hydrochloride?

The FDA Orange Book identifies approved reference products and associated patents or exclusivity where applicable. Adipex-P and Lomaira are relevant reference products for different strengths and presentations, while generic phentermine hydrochloride products may reference the applicable listed products depending on dosage form and strength. [3]

An applicant should distinguish between:

1. The reference listed drug used for ANDA submission.
2. The exact strength and dosage form supported by that reference product.
3. Any listed method-of-use or formulation patent.
4. The pediatric, labeling, or exclusivity status associated with the reference product.
5. Whether the proposed product has the same active ingredient, dosage form, strength, route, labeling, and pharmaceutical equivalence required for an ANDA.

Lomaira is commercially important because its 8 mg tablet supports lower-dose administration and flexible titration. A 37.5 mg tablet applicant should not assume that Lomaira’s regulatory or commercial attributes transfer to the lower-strength product.

Which excipients are used in phentermine hydrochloride products?

Commercial immediate-release phentermine products typically use conventional oral solid-dose excipients. Public product labeling identifies excipient systems that can include lactose, microcrystalline cellulose, starch or pregelatinized starch, colloidal silicon dioxide, and magnesium stearate, although the exact composition varies by manufacturer and dosage form. [1][4][5]

Core excipient functions

Formulation need	Common excipient strategy	Commercial rationale
Dilution of low drug load	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Supports tablet weight and content uniformity
Binding	Pregelatinized starch, povidone, hydroxypropyl cellulose	Improves granule and tablet integrity
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid release
Lubrication	Magnesium stearate, sodium stearyl fumarate	Improves compression and ejection
Flow control	Colloidal silicon dioxide	Reduces segregation and improves feeding
Taste masking	Film coating, ion-exchange resin, polymer barrier	Supports chewable or orally disintegrating products
Moisture control	Low-moisture excipients, desiccant packaging, protective blister	Improves stability for hygroscopic systems
Appearance and identification	Approved pigments, film coats, imprinting	Reduces medication-error risk

Excipients should be selected against the FDA Inactive Ingredient Database, compendial requirements, prior human exposure, and the applicable route and dosage form. [6] A formulation using a novel excipient would face a higher regulatory burden and offers little advantage for a mature, price-sensitive product unless it solves a clear performance problem.

How should companies design a phentermine hydrochloride excipient platform?

The most defensible platform uses a common excipient architecture across several strengths. A shared platform can reduce validation costs, simplify procurement, and support multiple ANDA products.

Immediate-release tablet platform

A conventional direct-compression or dry-granulation formulation is the lowest-risk approach. Microcrystalline cellulose can provide compactibility, while a disintegrant and low-level glidant support dissolution and manufacturing consistency. Magnesium stearate remains common, but over-lubrication must be controlled because it can slow dissolution and weaken tablet bonding.

For a 37.5 mg tablet, a direct-compression formulation may provide a low-cost path if the API has adequate flow and compressibility. If the API shows segregation or poor flow, dry granulation can improve blend uniformity without the moisture exposure associated with aqueous wet granulation.

Low-dose tablet platform

An 8 mg tablet creates a more demanding content-uniformity problem than a 37.5 mg tablet because the API represents a smaller proportion of total tablet mass. The formulation should prioritize:

• Ordered blending or geometric dilution.
• Controlled API particle-size distribution.
• Low-segregation excipients.
• Robust assay and content-uniformity testing.
• A tablet weight sufficient to support accurate dosing.
• A manufacturing process that limits electrostatic adherence and demixing.

The low-dose product has commercial value because it supports gradual titration and may be more convenient for patients who do not tolerate higher strengths.

Capsule platform

Hard capsules allow rapid development and can avoid some compression problems. They can also support bead, granule, or multiparticulate designs. Capsule disadvantages include higher packaging cost, greater sensitivity to shell moisture conditions, and less flexibility for tablet splitting.

Capsules may be attractive where a manufacturer wants a distinct product presentation without developing a complex release technology.

Orally disintegrating or rapidly dispersible tablet

An orally disintegrating tablet could differentiate phentermine through administration convenience. The formulation would need fast disintegration, acceptable mouthfeel, low friability, and control of the drug’s bitter or stimulant-like taste.

Potential excipient systems include mannitol for mouthfeel and bulking, crospovidone or croscarmellose sodium for rapid breakup, and a taste-masking polymer or coating. The commercial value depends on whether the product can demonstrate patient preference or adherence benefits without creating excessive manufacturing cost.

A true orally disintegrating tablet must meet applicable FDA expectations for rapid disintegration and handling. A tablet that merely disperses quickly in water should not be marketed as equivalent to an FDA-defined orally disintegrating product without appropriate regulatory support.

What commercial opportunities exist for phentermine hydrochloride?

1. Low-cost generic supply

The largest addressable opportunity remains reliable generic supply. Buyers include wholesalers, chain pharmacies, health systems, telehealth platforms, and pharmacy benefit managers. A supplier with dependable API access, multiple qualified excipient vendors, and dual-site manufacturing can gain share even without formulation novelty.

Supply interruptions have commercial value in mature generic markets because customers often switch suppliers quickly when a product is unavailable.

2. Lower-dose titration products

The 8 mg Lomaira-style segment offers a clearer product-positioning opportunity than another undifferentiated 37.5 mg tablet. A lower-strength product can support flexible dosing, dose reduction, and patients who experience adverse effects at higher doses.

The product must compete against tablet splitting, existing 15 mg and 30 mg capsules, and prescriber preference. Its value is strongest when supported by a compliant label and packaging that communicates dose flexibility without promoting off-label chronic use.

3. Patient-friendly administration

Orally disintegrating, chewable, or small-format tablets may address swallowing difficulty and convenience. Commercial success would depend on three factors:

• Demonstrated dosage-form benefit.
• Acceptable taste and stability.
• A price premium that survives generic substitution.

Taste masking is central. Phentermine’s pharmacology creates a strong incentive to avoid accidental exposure and unpleasant mouthfeel, particularly in a product intended to dissolve in the oral cavity.

4. Contract manufacturing and private-label supply

Phentermine products are suitable for contract manufacturing arrangements because the active ingredient, dosage forms, and excipient systems are established. Opportunities exist in:

• ANDA development partnerships.
• Private-label products for regional distributors.
• Dual-source supply agreements.
• Finished-dose manufacturing for telehealth and obesity-care platforms.
• Packaging and serialization services for controlled substances.

Controlled-substance handling requirements narrow the supplier pool and increase the value of compliant manufacturing infrastructure.

5. Export and geographic expansion

The commercial opportunity varies sharply by jurisdiction. Phentermine is controlled or restricted in multiple countries, and obesity-treatment labeling differs by market. A US-approved formulation cannot be assumed to qualify for approval elsewhere.

Geographic expansion requires review of:

• Local controlled-substance scheduling.
• Import permits and quota rules.
• Country-specific obesity-treatment guidelines.
• Maximum package sizes.
• Pharmacovigilance and abuse-monitoring requirements.
• Local excipient acceptability and labeling rules.

The US remains the most developed market for the established product class, while international opportunity is constrained by regulatory controls and competing anti-obesity therapies.

What manufacturing and intellectual-property barriers affect phentermine products?

The principal barriers are operational rather than patent-based.

Manufacturing barriers

Phentermine hydrochloride manufacturing requires controls for:

• API potency and assay variability.
• Blend uniformity, particularly in low-dose tablets.
• Segregation during transfer and compression.
• Dissolution after lubrication.
• Moisture and temperature exposure.
• Controlled-substance inventory reconciliation.
• Tamper-resistant storage and distribution.
• Cleaning validation and cross-contamination prevention.

A low-cost formulation can still fail commercially if it has dissolution variability, tablet defects, recurring observations, or unreliable API supply.

Intellectual-property barriers

Potential barriers include:

• Live formulation claims covering a specific excipient ratio or release profile.
• Patents on orally disintegrating or taste-masked dosage forms.
• Process claims that increase the cost of designing around a product.
• Trademark restrictions on product names and packaging.
• ANDA litigation following a Paragraph IV certification.

Because the base product is old, a credible patent strategy requires a technically narrow but commercially meaningful invention. Broad claims covering ordinary lactose, cellulose, starch, and magnesium stearate systems are unlikely to provide durable protection.

Which companies are challenging the phentermine hydrochloride market?

The market is populated by generic manufacturers and branded or branded-generic suppliers rather than by biosimilar developers. Known commercial products include Adipex-P, associated with Teva Pharmaceuticals, and Lomaira, associated with KVK-Tech, alongside multiple generic manufacturers. Product ownership, marketing authorization, and distribution arrangements can change over time and should be verified against current FDA listings and DailyMed records. [3][4][5]

Competition is based on:

• Wholesale acquisition cost.
• Guaranteed supply.
• Number of strengths.
• Tablet versus capsule availability.
• Contracting access.
• Packaging and dispensing convenience.
• Regulatory inspection history.
• Controlled-substance distribution capability.

There is no biosimilar risk because phentermine hydrochloride is a small-molecule drug. Competitive pressure comes from generic substitution and alternative obesity medicines, including GLP-1 receptor agonists and combination therapies.

What generic launch scenarios exist for phentermine hydrochloride?

Scenario 1: Standard ANDA launch

A conventional immediate-release tablet or capsule can enter through an ANDA if it demonstrates pharmaceutical equivalence and bioequivalence to the selected reference product. This is the lowest-development-risk strategy but also the most exposed to price erosion.

Scenario 2: Differentiated low-dose launch

An 8 mg or other lower-dose product can target titration and tolerability. The commercial opportunity is narrower, but price competition may be less intense than in the 37.5 mg segment.

Scenario 3: Patient-convenience formulation

An orally disintegrating or taste-masked product may command a premium if it demonstrates practical value. The regulatory pathway and development cost are higher, and the product may require a 505(b)(2) strategy if it cannot meet ANDA sameness requirements.

Scenario 4: Complex-release product

A sustained-release or abuse-deterrent product could create a differentiated product profile, but it would face substantial clinical, pharmacokinetic, abuse-liability, and regulatory requirements. The commercial case is weak unless the developer can demonstrate a clear advantage over inexpensive immediate-release products.

What patent litigation and settlement risks affect phentermine?

Phentermine has no widely recognized current litigation pattern comparable to heavily patented branded medicines. The main legal risks would arise from:

• A Paragraph IV challenge to a listed formulation or method-of-use patent.
• ANDA litigation involving a branded reference product.
• Trademark or trade-dress disputes.
• Controlled-substance distribution enforcement.
• Patent disputes over a new modified-release or orally disintegrating product.

A settlement agreement could delay generic entry if a live patent were asserted, but a settlement would need review under applicable antitrust and pharmaceutical-settlement standards. For standard phentermine hydrochloride products, regulatory execution and market access are generally more important than patent settlement strategy.

How strong is the phentermine hydrochloride patent estate?

The patent estate for conventional phentermine hydrochloride is weak from a lifecycle-management perspective because the active ingredient and basic immediate-release presentations are mature. A new entrant should not assume that a novel excipient combination alone creates strong exclusionary power.

Patent strength improves when a formulation provides:

• A clinically meaningful release profile.
• A reproducible pharmacokinetic advantage.
• A validated abuse-deterrent property.
• A specific stability improvement.
• A measurable adherence or administration benefit.
• A manufacturing process that is difficult to design around.

The strongest commercial protection may come from a combination of regulatory exclusivity, distinctive dosage form, reliable supply, trademarks, and customer contracts rather than from a broad composition patent.

How does phentermine compare with newer obesity medicines?

Phentermine has a low cost, established prescriber familiarity, oral administration, and simple manufacturing profile. Newer obesity medicines generally offer stronger chronic-treatment positioning and larger efficacy claims but have higher prices, more complex administration, and greater supply-chain or reimbursement constraints.

Attribute	Phentermine hydrochloride	Newer branded obesity medicines
Product age	Mature	Often recently developed
Typical cost structure	Low-cost generic	High-cost branded
Administration	Oral immediate-release products	Oral or injectable, depending on product
Patent position	Limited for conventional products	Often substantial
Manufacturing complexity	Low to moderate	Moderate to high
Chronic-use positioning	Limited by label and clinical practice	More established for selected products
Biosimilar exposure	None	Relevant mainly to biologic products
Differentiation opportunity	Dosage form, dose flexibility, supply	Efficacy, chronic use, delivery technology

Key Takeaways

• Phentermine hydrochloride is a mature Schedule IV small-molecule drug with extensive generic competition.
• Conventional immediate-release tablets and capsules have limited patent-based differentiation.
• The most practical excipient strategy uses familiar, compendial excipients with strong FDA precedent.
• Low-dose products create the clearest formulation opportunity because they require stronger content-uniformity and dose-flexibility controls.
• Orally disintegrating and taste-masked products offer potential patient-convenience differentiation but carry higher development and regulatory risk.
• Biosimilar risk is irrelevant; generic substitution and competing obesity therapies define the market.
• Manufacturing reliability, controlled-substance compliance, API supply, and contracting access are more important than broad patent exclusivity.
• A 505(b)(2) strategy may be appropriate for a genuinely differentiated dosage form, while a conventional equivalent product should generally pursue the ANDA route.
• Geographic expansion is constrained by country-specific controlled-substance rules and obesity-treatment labeling.
• A commercially strong product would combine a defensible dosage-form advantage with low manufacturing cost and dependable supply.

FAQs About Phentermine Hydrochloride Excipient and Commercial Strategy

Can lactose be used in phentermine hydrochloride tablets?

Yes. Lactose is used in some oral phentermine products and has broad FDA precedent. It may be unsuitable for specific patient populations or formulations where lactose intolerance, moisture sensitivity, or compressibility is a concern.

Is an extended-release phentermine product commercially attractive?

Potentially, but development risk is high. An extended-release product would need to demonstrate a clinically useful pharmacokinetic and tolerability profile while addressing abuse liability, bioequivalence, and the limited chronic-use positioning of conventional phentermine labeling.

Can phentermine hydrochloride be formulated as an orally disintegrating tablet?

Yes. The formulation would require rapid disintegration, acceptable taste, sufficient mechanical strength, controlled moisture exposure, and regulatory support for the proposed dosage-form claims.

Does phentermine hydrochloride qualify for a biosimilar pathway?

No. Phentermine hydrochloride is a chemically synthesized small molecule. Follow-on products use generic-drug pathways, primarily ANDAs, rather than biosimilar applications.

What is the most attractive commercial strength for a new phentermine product?

The lower-dose segment may offer more differentiation than the crowded 37.5 mg segment. An 8 mg or similarly flexible product can target titration and tolerability, but its market size and pricing must justify the added manufacturing and commercial investment.

References

1. U.S. Food and Drug Administration. (2023). Adipex-P (phentermine hydrochloride) prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2023). Lomaira (phentermine hydrochloride) prescribing information. FDA/DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. National Library of Medicine. (2024). DailyMed: Phentermine hydrochloride tablet and capsule labeling. https://dailymed.nlm.nih.gov/

5. National Library of Medicine. (2024). DailyMed: Adipex-P and Lomaira labeling. https://dailymed.nlm.nih.gov/

6. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-approval-status-drug-products-marketed-united-states